Imugene Ltd

Imugene (ASX: IMU) has received firm commitments for a $37.5 million capital raising to advance the development of off-the-shelf (allogeneic) CAR-T drug azer-cel for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company will raise an initial $22.5 million from the placement of 68.2 million shares priced at $0.33 each, a 22.4% discount to […]

Imugene (ASX: IMU) has announced positive results from a Phase 1b clinical trial using lead candidate azer-cel on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Ten enrolled patients had previously undergone up to five lines of cancer treatment for the non-Hodgkin’s lymphoma, including autologous chimeric antigen receptor (CAR) T-cell therapy—all of which […]

Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]

Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that a Phase 1 clinical trial of lead drug candidate onCARlytics has cleared its first cohort within the intra-tumoural monotherapy arm of the study. Known as OASIS, the first-in-class trial combines a CD19-expressing oncolytic virus that flags solid tumours for attack by CD19-targeting therapeutics such as […]